Product News

Share this article:
Merck's overseas affiliate MSD said that Isentress (raltegravir) has been granted a license from the European Union Commission for use in combination with other antiretroviral medicinal products for the treatment of HIV-1 infection in treatment-experienced adult patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy. The FDA granted approval for Isentress in October.

Pfizer said it received an FDA approvable letter for dalbavancin HCl, its once-weekly two-dose antibiotic under review for treating adults with complicated skin and skin structure infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA).
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA lifts OncoMed partial hold

The FDA froze the clinical trial of anti-Fzd7 vantictumab in July over concern about "bone-related adverse events."

Research links estrogen and binge eating

Baylor College of Medicine researchers have found that an estrogen replacement suppressed binge-eating behavior among lab mice.

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.